ScripThe capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir
ScripThe NASDAQ Biotech Index is down by nearly 27% since the last peak, the IPO window is virtually shut, there is diminished appetite for secondary offerings, the situation has been made worse by the col
ScripWhile biopharma executives, investors and deal-makers are busy presenting at the J.P. Morgan Healthcare Conference in San Francisco, global political attention is fixating on a deal signed thousands o
ScripSynthetic biology specialist Intrexon Corp. has shifted its focus exclusively to health care and is selling its agricultural, industrial and other biotechnology businesses. Going forward, Intrexon’s